BioNTech (BNTX) vs Gilead Sciences (GILD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gilead Sciences (GILD) has outperformed BioNTech (BNTX) over the past year, gaining 25.7% versus a loss of 10.2%. Over five years, GILD leads with a +117.1% price change compared with -61.5% for BNTX. Gilead Sciences is the larger company by market cap ($182.09 billion vs $23.93 billion), about 7.6 times the size.
Gilead Sciences pays a dividend yielding 2.19%, while BioNTech does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | GILD |
|---|---|---|
| Share price | $95.25 | $146.85 |
| Market cap | $23.93B | $182.09B |
| 1-day change | -0.50% | +1.82% |
| YTD return | +0.05% | +19.64% |
| 1-year return | -10.19% | +25.75% |
| 5-year return | -61.54% | +117.14% |
| Forward P/E | — | 14.85 |
| EPS (TTM) | $-7.83 | $-2.65 |
| Dividend yield | 0.00% | 2.19% |
| Annual dividend | $0.00 | $3.22 |
| Revenue (latest FY) | — | $29.44B |
| Revenue growth (YoY) | — | +2.40% |
| Net income (latest FY) | — | $8.51B |
| Gross margin | — | 78.83% |
| Operating margin | — | 34.04% |
| Net margin | — | 28.90% |
| 52-week high | $124.00 | $157.29 |
| 52-week low | $79.52 | $114.02 |
| Distance from 52-week high | -23.19% | -6.64% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +21.56% | +8.46% |
| Average volume | 1.16M | 6.02M |
| Shares outstanding | 251.20M | 1.24B |
| Employees | 7,807 | 17,000 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gilead Sciences is about 7.6 times larger than BioNTech by market value ($182.09B vs $23.93B).
- GILD has outperformed BNTX by 35.9 percentage points over the past year.
- Gilead Sciences offers a meaningfully higher dividend yield (2.19% vs 0.00%).
- The two companies sit in different sectors: BioNTech in Health Care and Gilead Sciences in Healthcare.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Healthcare · Drug Manufacturers - General · 17,000 employees
BNTX vs GILD FAQ
Which is bigger, BioNTech or Gilead Sciences?
Gilead Sciences (GILD) is larger, with a market capitalization of $182.09B compared with $23.93B for BioNTech (BNTX).
Which stock has performed better over the past year, BNTX or GILD?
GILD returned +25.75% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BioNTech or Gilead Sciences?
Gilead Sciences pays a dividend yielding 2.19%, while BioNTech does not currently pay a regular dividend.
Are BioNTech and Gilead Sciences in the same industry?
No. BioNTech is in the Health Care sector, while Gilead Sciences is in Healthcare.